Articles by Nicholas McAndrew
115 Evaluating an AI-Based Prognostic Test to Guide Adjuvant CDK4/6 Inhibitor Selection in Early HR+/HER2– Breast Cancer
ByNicholas McAndrew,Elena Diana Chiru,Aditya Bardia, MD, MPH, FASCO,Cerise Tang,Joseph Cappadona,Ken Zeng,Krzysztof Geras,Jan Witowski 116 Impact of Neoadjuvant Chemotherapy (NACT) Response on Clinical Outcomes With Ribociclib (RIB) in HR+/HER2− EBC: A Subgroup Analysis From the Phase 3 NATALEE Trial
ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Peter A. Fasching,Alejandro Rodriguez,Murat Akdere,Yogesh Chattar,Juan Pablo Zarate,Aditya Bardia, MD, MPH, FASCO 
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Aditya Bardia, MD, MPH, FASCO,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Karen Afenjar,Murat Akdere,Juan Pablo Zarate,Yogesh Chattar,Peter A. Fasching
